Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

What Was Tested

This registered phase 4 trial tested Tirzepatide for fat loss, obesity & body recomposition.

The aim of this clinical trial is to examine the effects of resistance training versus standard of care on contractile thigh muscle volume in patients receiving the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists 'tirzepatide'.

It had two arms (groups): Dual GIP/GLP-1 Receptor Agonist Tirzepatide (active comparator) and Dual GIP/GLP-1 Receptor Agonist Tirzepatide + Resistance Training (experimental).

The registry classes the interventions as behavioral and drug.

Who Took Part

150 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Are ≥ 18 years and ≤ 60 years of age. Have a body mass index (BMI) of ≥ 30 kg/m2. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. In the investigator's opinion, are well motivated, capable, and willing to. Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol.

The full record lists 14 inclusion and 41 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening); are currently breastfeeding; have structural cardiovascular disease (e.g., ischemic cardiovascular disease, heart failure, previous cerebrovascular accident \[stroke\]).

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the fat loss, obesity & body recomposition participants stayed in one arm throughout.

Blinding on both sides kept the fat loss, obesity & body recomposition participants and researchers unaware of who received Tirzepatide.

Those kept unaware of assignments: investigator and outcomes assessor.

It started in 2026-09-07 with completion listed for 2027-05-31.

It ran at 1 site in Germany.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI) (time frame: From baseline to the end of treatment at 24 weeks).

It also tracked 21 secondary outcomes, for example Change in body weight (kg), as assessed by a calibrated scale, Change in anterior thigh intramuscular fat fraction (%), as assessed by MRI, Change in contractile muscle volume of the combined scapular and upper back musculature (mL), as assessed by MRI, Change in combined whole-trunk and thigh fat volume (mL), as assessed by MRI, Change in peak isometric knee extension torque (Nm), as assessed using an isokinetic dynamometer and Change in maximum handgrip strength (kg), as assessed by a hand dynamometer.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide in 150 people with fat loss, obesity & body recomposition.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Fat loss, obesity & body recomposition research.